Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2012

01-08-2012 | Original Article

Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer

Authors: Wei Chua, Stephen J. Clarke, Kellie A. Charles

Published in: Supportive Care in Cancer | Issue 8/2012

Login to get access

Abstract

Background

Inflammatory markers are strong prognostic factors for survival in a variety of cancers. This study aimed to investigate the relationships between known inflammatory markers and their ability to predict overall survival (OS) in patients receiving docetaxel therapy.

Methods

Sixty-eight patients with advanced cancer were enrolled in a clinical trial of single agent docetaxel from 2000 to 2002. Inflammation was measured using baseline cytokine concentrations, acute phase reactant proteins and white blood cell counts. The neutrophil/lymphocyte ratio (NLR) and Glasgow Prognostic Score (GPS) were calculated. Associations between inflammatory markers and their predictive value for OS were tested.

Results

The majority of patients had elevated inflammatory markers (50–70%). Strong inter-relationships were observed between the different inflammatory indices. Only NLR and GPS were independently predictive of OS. A combined NLR and GPS score demonstrated 11 month differences in overall OS between patients with normal and elevated inflammatory status. Normalisation of NLR after three doses of chemotherapy was associated with significant improvement in survival.

Conclusion

This study found that NLR predicts the clinical outcomes for patients with advanced cancer treated with docetaxel. The clinical utilisation of NLR should be validated in a larger patient population to confirm its utility.
Literature
1.
2.
Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401–406PubMedCrossRef
3.
Anderson GM, Nakada MT, DeWitte M (2004) Tumor necrosis factor-[alpha] in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4:314–320PubMedCrossRef
4.
Michalaki KS, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 91:1227CrossRef
5.
Scambia UT, Benedetti Panici P, Foti' E, Martucci R, Gadducci A, Perillo A, Facchini V (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71:354–356PubMedCrossRef
6.
Blay J-Y, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani J-M, Moskovtchenko J-F, Philip T, Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322PubMed
7.
Chung YC, Chang CY (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226PubMedCrossRef
8.
De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21:45–52PubMedCrossRef
9.
Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13:575–382PubMed
10.
Andrews BEN, Shariat SF, Kim J-H, Wheeler TM, Slawin KM, Lerner SP (2002) Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167:1475–1481PubMedCrossRef
11.
Ledur AFC, David B, Hamberger C, Cavaillon JM (1995) Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J Immunol Methods 186:171–179PubMedCrossRef
12.
Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437–3444PubMedCrossRef
13.
Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA (2007) C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 107:114–117PubMedCrossRef
14.
Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, Ahn SV, Chung KY (2009) Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 63:106–110PubMedCrossRef
15.
Murri AMA, Bartlett JMS, Canney PA, Doughty JC, Wilson C, McMillan DC (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230PubMedCrossRef
16.
Sara R, Gavin WAL, Michael A, John G, Donald CM (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109:205–212CrossRef
17.
Sharma R, Hook J, Kumar M, Gabra H (2008) Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 44:251–226PubMedCrossRef
18.
Kishi Y, Kopetz S, Chun Y, Palavecino M, Abdalla E, Vauthey J-N (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16:614–622PubMedCrossRef
19.
Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JPA (2008) Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol (EJSO) 34:55–60CrossRef
20.
Gomez D, Farid S, Malik H, Young A, Toogood G, Lodge J, Prasad K (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32:1757–1762PubMedCrossRef
21.
Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425–428PubMedCrossRef
22.
Nakahara K, Monden Y, Ohno K, Fujii Y, Hashimoto J, Kitagawa Y, Kawashima Y (1987) Importance of biologic status to the postoperative prognosis of patients with stage III nonsmall cell lung cancer. J Surg Oncol 36:155–160PubMedCrossRef
23.
Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184PubMedCrossRef
24.
Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472PubMedCrossRef
25.
Chua WCK, Baracos VE, Clarke SJ (2011) Neutrophil–lymphocyte ratio (NLR) predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104:1288–1295PubMedCrossRef
26.
Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ (2006) Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet 45(6):611–612PubMedCrossRef
27.
Slaviero KA, Clarke SJ, McLachlan AJ, Blair EYL, Rivory LP (2004) Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57:44–53PubMedCrossRef
28.
Slaviero KA, Read JA, Clarke SJ, Rivory LP (2003) Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 46:148–157PubMedCrossRef
29.
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030PubMedCrossRef
30.
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90:1704–1706PubMed
31.
Halazun K, Hardy MA, Rana AA, Woodland DC, Luyten EJ, Mahadev S, WItkowski P, Stegel AB, Brown RS, Emond JC (2009) Negative impact of neutrophil lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 250:141–151PubMedCrossRef
32.
Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, Rabillon F, Dieras V, Jullien V, Hacrait P, Pons G, Treluyer JM et al (2007) Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Surg Oncol 18:168–172
33.
Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR (2006) Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 12:7492–7497PubMedCrossRef
Metadata
Title
Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer
Authors
Wei Chua
Stephen J. Clarke
Kellie A. Charles
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 8/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1289-3

Other articles of this Issue 8/2012

Supportive Care in Cancer 8/2012 Go to the issue

Original Article

Racial disparities in physical and functional domains in women with breast cancer

Original Article

Partner-assisted emotional disclosure for patients with GI cancer: 8-week follow-up and processes associated with change

Original Article

Preliminary development of a lymphedema symptom assessment scale for patients with head and neck cancer

Original Article

Illness appraisal, religious coping, and psychological responses in men with advanced cancer

Original Article

Prevalence and correlates of symptoms and uncertainty in illness among head and neck cancer patients receiving definitive radiation with or without chemotherapy

Original Article

Prospective assessment of health-related quality of life in patients with low-grade glioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits